Claritev (CTEV) Stock Price, News & Analysis

Company Overview

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design. By focusing on purpose-built solutions that support all key players — including payors, employers, patients, providers and third parties — we aim to make healthcare more accessible and affordable for all. 

Key Stats

• Today's Range: $25.57 to $27.00
• 50-Day Range: $13.45 to $25.87
• 52-Week Range: $12.04 to $74.07
• Volume: 14,571 shs
• Average Volume: 174,536 shs
• Market Capitalization: $442.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.25
• Consensus Rating: Moderate Buy

Claritev Stock Analysis - MarketRank™

Claritev scored higher than 55% of companies evaluated by MarketBeat, and ranked 364th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Claritev has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Claritev is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Claritev has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Claritev are expected to grow in the coming year, from ($14.44) to ($11.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Claritev is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Claritev is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CTEV.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Claritev does not currently pay a dividend.

Dividend Growth

Claritev does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.90

News Sentiment

Claritev has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Claritev this week, compared to 2 articles on an average week.

Company Ownership

• Score: 4.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Claritev in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $899,437.00 in company stock, which represents 0.2100% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Claritev insiders have bought more of their company's stock than they have sold. Specifically, they have bought $899,437.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of Claritev is held by insiders.

Percentage Held by Institutions

87.15% of the stock of Claritev is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CTEV Stock Analysis - Frequently Asked Questions

How have CTEV shares performed this year?

Claritev's stock was trading at $42.78 at the beginning of 2026. Since then, CTEV shares have decreased by 39.5% and is now trading at $25.87.

How were Claritev's earnings last quarter?

Claritev (NYSE:CTEV) released its quarterly earnings results on Thursday, August, 1st. The company reported ($1.20) earnings per share for the quarter, beating the consensus estimate of ($1.60) by $0.40. The firm earned $233.48 million during the quarter, compared to analysts' expectations of $253.59 million.
Read the conference call transcript.

When did Claritev's stock split?

Claritev's stock reverse split on the morning of Monday, September 23rd 2024.The 1-40 reverse split was announced on Tuesday, September 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Claritev's major shareholders?

Top institutional investors of Claritev include Bank of New York Mellon Corp (0.11%). Insiders that own company stock include Douglas Michael Garis, Michael Kim, William B Mintz, Tara O'neil, Travis Dalton, Corporate Investors Viii H&F and Anthony Colaluca Jr.
View institutional ownership trends.

How do I buy shares of Claritev?

Shares of CTEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/01/2024
• Today: 5/06/2026
• Next Earnings (Confirmed): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Business services, not elsewhere classified
• Sub-Industry: Business Services
• Current Symbol: NYSE:CTEV
• CIK: 1793229
• Web: www.claritev.com
• Phone: 1-800-677-1098
• Fax: N/A
• Employees: 3,000
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Claritev: $27.25
• High Price Target: $38.00
• Low Price Target: $21.00
• Potential Upside/Downside: +2.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($17.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$284.28 million
• Net Margins: -29.45%
• Pretax Margin: -38.64%
• Return on Equity: N/A
• Return on Assets: -3.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.86
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: $965.41 million
• Price / Sales: 0.46
• Cash Flow: $16.29 per share
• Price / Cash Flow: 1.64
• Book Value: ($10.10) per share
• Price / Book: -2.64

Miscellaneous

• Outstanding Shares: 16,553,000
• Free Float: 15,328,000
• Market Cap: $442.13 million
• Optionable: Optionable
• Beta: 0.76